What Pharma Firms Should Be Doing Now To Prepare For A ‘No Deal’ Brexit
As Brexit uncertainty continues and a “no-deal” scenario remains a possibility, pharmaceutical companies need to be looking at issues such as the renegotiation of supplier contracts, the transfer of key regulatory roles, and the mapping of trade flows, says EFPIA’s president, Stefan Oschmann. Meanwhile, industry and healthcare organizations have drawn up a list of “crucial unanswered questions” that they say the Brexit negotiators must address.
You may also be interested in...
The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."
The EU has agreed to a Brexit transition period and adopted guidelines on its talks with the UK on their future relationship. But while the political agreement on the transition will give the life sciences industry some certainty, it is not yet a done deal and the regulatory implications are still unclear.
The UK may not be able to participate in the European Medicines Agency after Brexit, but there are plenty of precedents for informal collaboration among regulatory agencies worldwide. A former European Medicines Agency executive director and legal experts talk to the Pink Sheet about what might be possible.